Twist Gene Fragments shipped starting at two business days regardless of length, volume, configuration or delivery format Gene Fragments pricing from seven cents per base regardless of configuration, no hidden fees SOUTH SAN FRANCISCO, Calif. / Jul 07, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector,... Read More

Offer end-to-end workflow from library prep through sequencing Twist to be sole provider of new Trinity™ library prep and target enrichment kits for Element AVITI™ sequencer Joint commercial activities to expand customer access to new NGS tools SOUTH SAN FRANCISCO, Calif. & SAN DIEGO / May 22, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life... Read More

SOUTH SAN FRANCISCO, Calif. / May 15, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will present at the William Blair 45th Annual Growth Stock Conference on Tuesday June 3, 2025 at 10:00 am Central Time in Chicago,... Read More

SOUTH SAN FRANCISCO, Calif. / May 13, 2025 / Business Wire / As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 72,991 equity awards, consisting of 53,600 restricted stock units (“RSUs”) and up to 19,379... Read More

New terms provide Twist with key license to long DNA technology and assets Ginkgo to continue ordering from Twist with no purchase minimums SOUTH SAN FRANCISCO, Calif. & BOSTON / May 08, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading... Read More

SOUTH SAN FRANCISCO, Calif. / May 05, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the second quarter fiscal 2025 ended March 31, 2025. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at... Read More

Spin out expected to unlock value by accelerating data storage technology development and allowing each company to focus strategically on its unique products, customers and investors Atlas Data Storage, a newly formed company, will focus solely on DNA data storage technology and commercialization, with $155 million in seed financing round including ARCH Venture Partners, Deerfield Management, Bezos Expeditions, Tao Capital... Read More

Adds to robust offering of NGS tools enabling exome sequencing, whole genome sequencing, RNA sequencing, deep sequencing for liquid biopsy research and MRD, and methylation detection Diverse portfolio of adapter sets now includes industry leading number of unique indexes at 3,072 HT UDI Adapters Enables multiplexing and high throughput sequencing SOUTH SAN FRANCISCO, Calif. / Apr 24, 2025 / Business Wire / Twist Bioscience... Read More

Company to host conference call at 8:00 AM ET SOUTH SAN FRANCISCO, Calif. / Apr 14, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, before the opening of the market on May 5, 2025. The... Read More

Collaboration to enable cost-effective end-to-end genotyping across large animal and plant populations Companies to present poster at AGBT-Ag SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich. / Mar 31, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Curio Genomics , a pioneer in genomics software, today... Read More

Supports Acceleration of Research Across Multiple Industries; Maximizes Budget SOUTH SAN FRANCISCO, Calif. / Mar 11, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that, for a limited time, all Twist Express Genes orders placed by academic customers globally will be shipped in as few as... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 25, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that its executives will participate in fireside chats at the following upcoming investor conferences: Emily Leproust, Ph.D., CEO and co-founder, and Adam Laponis, CFO, will participate in a fireside... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 19, 2025 / Business Wire / As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 123,024 equity awards, consisting of 72,394 restricted stock units (“RSUs”) and up to 50,630... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 03, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the first quarter fiscal 2025 ended December 31, 2024. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at... Read More

Company to host conference call at 8:00 AM ET SOUTH SAN FRANCISCO / Jan 22, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, before the opening of the market on February 3, 2025. The company... Read More

SOUTH SAN FRANCISCO / Dec 19, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. Pacific Time in San Francisco,... Read More

SOUTH SAN FRANCISCO, Calif. / Nov 18, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the fourth quarter and full year fiscal 2024 ended September 30, 2024. Visit the Events and Presentations page of the Investor Relations section under the... Read More

SOUTH SAN FRANCISCO / Nov 14, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the 7 th Annual Evercore HealthCONx... Read More

SOUTH SAN FRANCISCO, Calif. / Nov 07, 2024 / Business Wire / As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 147,800 equity awards, consisting of 110,300 restricted stock units (“RSUs”)... Read More

Normalization by Ligation™ library preparation technology processes thousands of samples at low cost with enhanced multiplexing and novel streamlined workflow Designed with a Twist-developed enzyme specifically to increase adoption of NGS workflows in high throughput applications Collaboration with Gencove to offer access to software to perform genomic analysis, enabling an end-to-end sample to variant call workflow SOUTH... Read More

Company to host conference call at 8:00 AM ET SOUTH SAN FRANCISCO, Calif. / Oct 24, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, before the opening of the... Read More

Twist to retain all upfront, service and other revenue earned under antibody discovery and biopharma solutions agreements as well as half of future milestones and royalties SOUTH SAN FRANCISCO, Calif. / Oct 22, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered... Read More

SOUTH SAN FRANCISCO, Calif. / Oct 15, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more... Read More

SOUTH SAN FRANCISCO, Calif. / Sep 09, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today released its 2024 corporate responsibility report detailing Twist’s approach to sustainability, social responsibility and ethics. The report highlights Twist’s ongoing commitment to advancing... Read More

SOUTH SAN FRANCISCO, Calif. / Aug 27, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Baird Global Healthcare Conference 2024 in New York City on Tuesday, September 10 at 2:35 p.m.... Read More

Industry leading product available through Twist ecommerce platform Twist Gene Fragments now available up to 5.0kb in length with the same speed, quality, and affordability as shorter fragments Turnaround time starting at two business days SOUTH SAN FRANCISCO, Calif. / Aug 08, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality... Read More

SOUTH SAN FRANCISCO, Calif. / Aug 06, 2024 / Business Wire / As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 94,200 restricted stock units (“RSUs”) to 30 recently hired individuals as... Read More

SOUTH SAN FRANCISCO, Calif. & TOKYO / Aug 05, 2024 / Business Wire / Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and bitBiome Inc. , a biotechnology company unlocking the potential of our planet’s microbes to power the future of the bioeconomy, today announced the launch of a joint Transaminase Enzyme... Read More

Record revenue of $81.5M in 3QFY24, an increase of 28% over $63.7M in 3QFY23 Gross margin improved to 43.3% in 3QFY24, increasing approximately 900 basis points over 34.4% in 3QFY23 Increased FY 2024 revenue guidance to approximately $310M to $311M; FY 2024 gross margin guidance at high end of the range at approximately 42.0% Company to host conference call today at 8:00 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif. / Aug... Read More

Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors SOUTH SAN FRANCISCO, Calif. / Jul 18, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the first patient has been dosed in Pure Biologics’ exploratory Phase 0... Read More

Company to host conference call at 8:00 AM ET SOUTH SAN FRANCISCO, Calif. / Jul 11, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, before the opening of the market on Friday,... Read More

Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days SOUTH SAN FRANCISCO, Calif. / Jul 10, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its... Read More

NGS-verified synthetic control covers 99.9% of HA and NA genome regions SOUTH SAN FRANCISCO, Calif. / Jul 09, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its growing portfolio of synthetic viral controls with the launch of a synthetic RNA control for... Read More

TB206-001 shown to be a high-affinity, cross-reactive humanized antibody antagonist of A 2A R with in vivo tumor suppressing activity TB206-001 available for out-licensing SOUTH SAN FRANCISCO, Calif. / Jun 06, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the publication... Read More

Twist joins leading AI stakeholders to help advance the development and deployment of safe, trustworthy AI under new U.S. Government safety institute SOUTH SAN FRANCISCO, Calif. / Jun 04, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the company has joined the U.S.... Read More

SOUTH SAN FRANCISCO, Calif. / May 23, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will present and participate in fireside chats at the following upcoming investor conferences: Patrick Finn, Ph.D., president and COO, will participate in a fireside... Read More

No limit to number of fragments included in the pools Optimized chemistry enables direct synthesis of up to 500 bp double stranded fragments SOUTH SAN FRANCISCO, Calif. / May 13, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Multiplexed Gene Fragments... Read More

SOUTH SAN FRANCISCO, Calif. / May 08, 2024 / Business Wire / As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 87,200 restricted stock units (“RSUs”) to 26 recently hired individuals as... Read More

Record revenue of $75.3M in 2QFY24, an increase of 25% over $60.2M in 2QFY23 Orders increased to $93.2M in 2QFY24, growth of 45% over $64.2M in 2QFY23 Increased FY 2024 revenue guidance to a range of $300M to $304M; Increased FY 2024 gross margin guidance to a range of 41.5 to 42.0% Company to host conference call today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif. / May 02, 2024 / Business Wire / Twist Bioscience... Read More

Company to host conference call at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. / Apr 18, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, after market close on Thursday, May 2,... Read More

SOUTH SAN FRANCISCO, Calif. / Mar 28, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a new Human Pangenome Spike-in for the Twist Exome 2.0 panel developed to enable researchers to detect a more complete view of genetic variation during whole exome... Read More

Precision Dx Products are CE-marked and compliant with EU IVDR 2017/746 regulations Precision Dx Products include Twist Precision Prep and Enrichment Dx Kit, Twist Precision Exome Dx Panel and Twist Precision Exome Dx Kit SOUTH SAN FRANCISCO, Calif. / Mar 05, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 22, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will participate in fireside chats at the following upcoming investor conferences: Patrick Finn, Ph.D., president and COO, and Adam Laponis, CFO, will participate in a... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 07, 2024 / Business Wire / As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 122,400 restricted stock units (“RSUs”) to 36 recently hired individuals as... Read More

Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow expected to be available soon SOUTH SAN FRANCISCO, Calif. & SAN DIEGO / Feb 06, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc. , developer of pioneering technologies to empower science,... Read More

High accuracy and detection to identify tumor variants from degraded and low input samples as well as samples with limited DNA abundance Library preparation kit adds to Twist’s portfolio of tools to enable liquid biopsy applications SOUTH SAN FRANCISCO, Calif. / Feb 06, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic... Read More

Early access of novel technology that enables preparation of thousands of samples at low cost through self-normalization, enhanced multiplexing, and streamlined workflow Innovative solution positioned to drive NGS adoption in AgBio Twist Flex Prep UHT Kit and additional NGS tools to be highlighted at AGBT General Meeting SOUTH SAN FRANCISCO, Calif. / Feb 05, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST),... Read More

Record revenue of $71.5M in 1QFY24, an increase of 32% over $54.2M in 1QFY23 Orders increased to $77.5M in 1QFY24, an increase of 19% over 1QFY23 Increased FY 2024 revenue guidance to $288M to $293M; Increased FY 2024 gross margin guidance to 40% to 41% SOUTH SAN FRANCISCO, Calif. / Feb 02, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of... Read More

SOUTH SAN FRANCISCO, Calif. / Jan 24, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of Twist Express Genes , a new leading gene synthesis service with an order to shipping turnaround starting at five business days 1 , to include larger DNA preparations up... Read More

SOUTH SAN FRANCISCO, Calif. / Jan 16, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 first quarter ended December 31, 2023, before the opening of the market on Friday, February 2, 2024. The company plans to hold... Read More

SOUTH SAN FRANCISCO, Calif. / Jan 08, 2024 / Business Wire / As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 50,000 restricted stock units (“RSUs”) and 70,000 shares subject to the... Read More

SOUTH SAN FRANCISCO, Calif. / Jan 05, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Adam Laponis as chief financial officer. Mr. Laponis brings... Read More

SOUTH SAN FRANCISCO, Calif. / Dec 18, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 5:15 p.m. Pacific Time in... Read More

Record revenue of $245.1 million in Fiscal 2023; Increase of 20% over $203.6 million in Fiscal 2022 Orders increased to $264 million in Fiscal 2023; Increase of 17% over $226.4 million in Fiscal 2022 Expect revenue in the range of $285 million to $290 million for full year Fiscal 2024 SOUTH SAN FRANCISCO, Calif. / Nov 17, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to... Read More

Clonally perfect genes shipped in as few as five business days Launch of ‘fast genes’ enabled by state-of-the-art Wilsonville manufacturing facility SOUTH SAN FRANCISCO, Calif. / Nov 14, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist Express Genes , a... Read More

SOUTH SAN FRANCISCO, Calif. / Nov 13, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a fireside chat at the 6 th Annual Evercore ISI... Read More

SOUTH SAN FRANCISCO, Calif. / Nov 08, 2023 / Business Wire / As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 130,400 restricted stock units (“RSUs”) to 15 recently hired individuals as an inducement material to... Read More

SOUTH SAN FRANCISCO, Calif. / Nov 02, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 fourth quarter and full year ended September 30, 2023, before the opening of the market on Friday, November 17, 2023. The... Read More

Adds to robust offering of NGS tools enabling exome sequencing, whole genome sequencing, RNA sequencing and methylation detection Enables multiplexing and high throughput sequencing New offering expands and complements Twist’s portfolio of universal adapters Twist Full Length UDI Adapters to be highlighted at ASHG 2023 SOUTH SAN FRANCISCO, Calif. / Oct 31, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a... Read More

SOUTH SAN FRANCISCO, Calif. / Oct 05, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an antibody discovery, option and license agreement with Bayer. Under the terms of the agreement, Twist Biopharma Solutions, a division of Twist Bioscience, will leverage its Library of... Read More

SOUTH SAN FRANCISCO, Calif. / Oct 03, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mark Buck as senior vice president, operations. Mr. Buck brings experience improving manufacturing efficiency and driving revenue and margin through managing supply... Read More

SOUTH SAN FRANCISCO, Calif. & SAN RAFAEL, Calif. & BARCELONA / Sep 27, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and IMIDomics, Inc ., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced a multi-program... Read More

SOUTH SAN FRANCISCO, Calif. / Sep 05, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences: Baird 2023 Global Healthcare... Read More

SOUTH SAN FRANCISCO, Calif. / Aug 31, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a drug discovery agreement with Ono Pharmaceutical Co. , Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) to discover and develop novel antibodies for the treatment of autoimmune... Read More

SOUTH SAN FRANCISCO, Calif. / Aug 22, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today released its environmental, social and governance (ESG) report for 2023 , highlighting Twist’s... Read More

SOUTH SAN FRANCISCO, Calif. / Aug 07, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Patrick Finn, Ph.D., president and COO of Twist Bioscience, will participate in the Innovation Across Drug Discovery, Molecule Synthesis, & Precision Medicine panel at the UBS... Read More

Record revenue of $63.7M in 3QFY23; Increase of 14% over $56.1M in Fiscal 2022 Orders increased 7% in 3QFY23 over fiscal 2022 to $63.8M SOUTH SAN FRANCISCO, Calif. / Aug 04, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the... Read More

SOUTH SAN FRANCISCO, Calif. / Jul 20, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 third quarter ended June 30, 2023, before the opening of the market on Friday, August 4, 2023. The company plans to hold a... Read More

Cancer Research Horizons is the innovation arm of Cancer Research UK SOUTH SAN FRANCISCO, Calif. / Jul 18, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Cancer Research Horizons , the innovation engine at the core of one of the world’s largest private funders of cancer research,... Read More

TB-222-023 Discovered and Optimized Using Twist’s Synthetic DNA Libraries and Antibody Engineering Services SOUTH SAN FRANCISCO, Calif. / Jun 26, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced publication of preclinical data supporting the potential use of the highly... Read More

SOUTH SAN FRANCISCO, Calif. / Jun 20, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Chet Gandhi as chief information officer. Mr. Gandhi brings a wealth of experience in leading and executing software and information technology strategies to enable the... Read More

RNA fusions can be used as biomarkers to identify cancer sub-types and monitor for residual disease SOUTH SAN FRANCISCO, Calif. / May 31, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and CeGaT GmbH , a global provider of sequencing services for research, clinical studies, and human... Read More

SOUTH SAN FRANCISCO, Calif. / May 24, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences: William... Read More

SOUTH SAN FRANCISCO, Calif. / May 23, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Robert Werner as chief accounting officer. “Rob has a proven track record of leading corporate and technical accounting, including for global companies as they grow in... Read More

Includes Twist RNA Exome, target enrichment for RNA and whole transcriptome sequencing SOUTH SAN FRANCISCO, Calif. / May 22, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a portfolio of RNA sequencing tools , which includes the Twist RNA Exome, Twist RNA... Read More

SOUTH SAN FRANCISCO, Calif. / May 10, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at Imec Technology Forum (ITF) World 2023 in Antwerp, Belgium on Wednesday, May 17 th at 11:10 AM CEST.... Read More

Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22 Orders increased to $64.2M in 2QFY23; up 17% over 2QFY22 Decisive Actions to Accelerate Path to Profitability SOUTH SAN FRANCISCO, Calif. / May 05, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial... Read More

Comprehensive capture panel to enable enhanced bioinformatics-based oncology research SOUTH SAN FRANCISCO, Calif. & TAMPA, Fla. / Apr 27, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Aster Insights , a bioinformatics company with the most advanced, direct-patient,... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 20, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura., “Astellas”), by which Astellas will license a suite of Twist’s VHH antibody libraries to be used... Read More

TCR and CAR libraries enable comprehensive screening of combinations of custom gene parts including domains from TCRs and CARs Information about the offering available at AACR Annual Meeting 2023 SOUTH SAN FRANCISCO, Calif. / Apr 13, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today... Read More

SOUTH SAN FRANCISCO / Apr 13, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 second quarter ended March 31, 2023, before the opening of the market on Friday, May 5, 2023. The company plans to hold a conference... Read More

SOUTH SAN FRANCISCO, Calif. / Mar 09, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an integrated offering of antibody discovery services available to customers. The offering combines Twist Biopharma’s synthetic libraries and AI machine learning with an in vivo... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 28, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences: Cowen 43 rd... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 14, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today published on the successful discovery of alpaca-derived VHH antibodies using a disruptive, function-forward in vivo discovery workflow developed by Abveris, also known as Twist Boston, on the... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 07, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced technology early access of the Twist enhanced Whole Genome Sequencing (eWGS) solution focused on non-human genomics applications, at the Advances in Genome Biology and Technology (AGBT)... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 03, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2023 ended December 31, 2022. "We had a very good start to the year with solid revenue across SynBio, NGS and... Read More

110,000 square-foot state-of-the-art facility supports significantly expanded product manufacturing capacity and will enable new product introductions SOUTH SAN FRANCISCO, Calif. / Jan 26, 2023 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of... Read More

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022, before the opening of the market on Friday, February 3, 2023. The company plans to hold a conference call and live audio webcast for analysts and... Read More

Combining expertise to advance precision medicine, while enabling efficient and timely insights into the diagnosis of rare diseases and hereditary cancer around the world Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers... Read More

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a research collaboration with Astellas Pharma Inc . (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) to discover antibodies against multiple targets of interest to develop curative therapies for patients suffering from diseases... Read More

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 41st Annual J.P. Morgan Health Care Conference on Monday, January 9th at 5:15 p.m. PST / 8:15 p.m. EST. The presentation will be webcast live and can be... Read More